Sanofi’s mega US$1.6 billion Vicebio buyout once again shows the value of Aussie uni IP

French pharma giant Sanofi will pay US $1.15 billion up‑front—and up to another US$450 million in milestones—to acquire Vicebio, a biotech set up to commercialise the University of Queensland’s Molecular Clamp vaccine platform.

UQ licensed the tech to Vicebio in 2018 through its commercialisation arm UniQuest. The university will remain a shareholder as the deal propels the platform toward late‑stage trials and market launch.

It’s is the richest exit for intellectual property developed at an Australian university, eclipsing UQ spin‑outs Inflazome (which sold to Roche for $620 million in 2020) and Spinifex Pharmaceuticals (US $700 million sale to Novartis in 2015).

“This extraordinary outcome validates 12 years of UQ research, and I pay tribute to the dedicated UQ scientists who invented the patented Molecular Clamp technology,” said UQ Vice-Chancellor Professor Deborah Terry AC.

“Professor Keith Chappell, Professor Daniel Watterson and Emeritus Professor Paul Young have a tremendous passion for research that delivers for the public good and they exemplify what we strive for at UQ.

“The acquisition is a compelling vote of confidence in the strength of Australian university research to develop innovations that can be translated into life-saving solutions with a world-leader in the vaccine space.”

Vicebio was seeded by European life‑sciences fund Medicxi with €18 million and built around the Molecular Clamp, a synthetic ‘pin’ that locks viral fusion proteins into their infection‑ready shape, producing stronger immune responses and potentially cheaper, single dose vaccines.

Professors Keith Chappell, Dan Watterson and Paul Young shot to prominence in 2020 when their COVID‑19 candidate was shelved after HIV‑test cross‑reactivity.

That setback, detailed in Nature, accelerated work on a second‑generation clamp and confirmed the platform’s versatility across more than 10 viral families.

“A key advantage of the Molecular Clamp platform is that it streamlines vaccine development across different viral families,” Professor Chappell said.

“This is incredibly important for outbreak responses but facilitates the efficient development of multi-pathogen vaccines that we believe will protect vulnerable populations against common viruses that cause severe respiratory diseases.

“Of course, we will never forget the outpouring of support and the funding from Australian and Queensland governments and donors during the pandemic that enabled us to rapidly develop a vaccine candidate and to conduct a phase 1 clinical trial in Australia.

The sunshine state is in a VC and startup heatwave right now with a recent report from Cut Through Ventures finding Queensland funding levels surged 37% in the last financial year.